Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

The identification of antigens associated with tumor destruction is a major goal of cancer immunology. Vaccination with irradiated tumor cells engineered to secrete granulocyte–macrophage colony stimulating factor generates potent, specific, and long-lasting antitumor immunity through improved tumor antigen presentation by dendritic cells and macrophages. A phase I clinical trial of this immunization strategy in patients with disseminated melanoma revealed the consistent induction in distant metastases of dense T and B cell infiltrates that effectuated substantial tumor necrosis and fibrosis. To delineate the target antigens of this vaccine-stimulated tumor destruction, we screened a melanoma cDNA expression library with postimmunization sera from a long-term responding patient (K030). High-titer IgG antibodies recognized melanoma inhibitor of apoptosis protein (ML-IAP), a caspase antagonist containing a single baculoviral IAP repeat and a COOH-terminal RING domain. Although K030 harbored antibodies to ML-IAP at the time of study entry, multiple courses of vaccination over 4 years increased antibody titers and elicited isotype switching. Moreover, lymphocyte infiltrates in necrotic metastases included CD4+ and CD8+ T cells specific for ML-IAP, as revealed by proliferation, tetramer, enzyme-linked immunospot, and cytotoxicity analysis. Whereas melanoma cells in densely infiltrated lesions showed strong ML-IAP expression by immunohistochemistry, lethal disease progression was associated with the loss of ML-IAP staining and the absence of lymphocyte infiltrates. These findings demonstrate that ML-IAP can serve as a target for immune-mediated tumor destruction, but that antigen-loss variants can accomplish immune escape.

[1]  J. Lieberman,et al.  Granzymes A and B directly cleave lamins and disrupt the nuclear lamina during granule-mediated cytolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[2]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[3]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[4]  Lloyd J. Old,et al.  New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.

[5]  K. Kamiguchi,et al.  An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  E. Jaffee,et al.  The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. , 2001, Cancer research.

[7]  R S Warren,et al.  Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization , 1999, Genes, chromosomes & cancer.

[8]  K. Sakaguchi,et al.  Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[9]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[10]  V. Dixit,et al.  SMAC Negatively Regulates the Anti-apoptotic Activity of Melanoma Inhibitor of Apoptosis (ML-IAP)* , 2002, The Journal of Biological Chemistry.

[11]  T. Hercend,et al.  A natural cytotoxic T cell response in a spontaneously regressing human melanoma targets a neoantigen resulting from a somatic point mutation , 1999, European journal of immunology.

[12]  C. Figdor,et al.  Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[13]  T. Ley,et al.  DFF45/ICAD can be directly processed by granzyme B during the induction of apoptosis. , 2000, Immunity.

[14]  N. Thornberry,et al.  Granzyme B directly and efficiently cleaves several downstream caspase substrates: implications for CTL-induced apoptosis. , 1998, Immunity.

[15]  D. Neuberg,et al.  Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Mulligan,et al.  A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[17]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[18]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[19]  J. Lin,et al.  KIAP, a novel member of the inhibitor of apoptosis protein family. , 2000, Biochemical and biophysical research communications.

[20]  D. B. Yehuda,et al.  Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern , 2001, FEBS letters.

[21]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[22]  P. Cresswell,et al.  Impaired assembly and transport of HLA‐A and ‐B antigens in a mutant TxB cell hybrid. , 1986, The EMBO journal.

[23]  A. Halpern,et al.  Model predicting survival in stage I melanoma based on tumor progression. , 1989, Journal of the National Cancer Institute.

[24]  L K Miller,et al.  An exegesis of IAPs: salvation and surprises from BIR motifs. , 1999, Trends in cell biology.

[25]  J. Becker,et al.  Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. , 2001, Cancer research.

[26]  Jongdae Lee,et al.  IAP Suppression of Apoptosis Involves Distinct Mechanisms: the TAK1/JNK1 Signaling Cascade and Caspase Inhibition , 2002, Molecular and Cellular Biology.

[27]  J. Trapani,et al.  Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme B–Mediated Caspase Activation , 2000, The Journal of experimental medicine.

[28]  J. Trent,et al.  Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma , 1997, Genes, chromosomes & cancer.

[29]  W. Hahn,et al.  The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. , 1999, Immunity.

[30]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[31]  M. Mihm,et al.  Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[32]  G M Kasof,et al.  Livin, a Novel Inhibitor of Apoptosis Protein Family Member* , 2001, The Journal of Biological Chemistry.

[33]  F. Alt,et al.  Mechanism and control of class-switch recombination. , 2002, Trends in immunology.

[34]  J C Reed,et al.  IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.

[35]  E. Jaffee,et al.  Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. , 1994, Science.

[36]  D. Neuberg,et al.  ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[37]  T. Hercend,et al.  A MAGE‐6‐encoded peptide is recognized by expanded lymphocytes infiltrating a spontaneously regressing human primary melanoma lesion , 1999, European journal of immunology.

[38]  M. Mihm,et al.  Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. , 2000, Cancer research.

[39]  G. Salvesen,et al.  ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas , 2000, Current Biology.

[40]  D. Green,et al.  Granzyme B–Mediated Cytochrome C Release Is Regulated by the Bcl-2 Family Members Bid and Bax , 2000, The Journal of experimental medicine.